

Company Profile

mondobIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE) is an independent Swiss biotech company that discovers drugs for patients suffering from rare diseases. The company discovers these drugs by utilizing its proprietary Search & Match methodology and then validates such drugs by its Community of leading experts in the Orphan Diseases Market.

Subsequent to proof-of-concept, Mondobiotech seeks strategic partnerships to complete the development of its drugs through the regulatory approval and commercialization.

The current pipeline of the company is comprised of 8 MPCs ready for licensing and an additional 73 MPCs in various development stages

Business model

Mondobiotech's approach to medicine is based on the following key elements:

- Focused research on peptides for the treatment of rare diseases. Peptides are short polymers of amino acids and can often provide for an exceptional safety and pharmacology profile. The Rare Disease Market consists of more than 7,000 diseases, affecting over 500 million patients worldwide.
- Search&Match methodology for the discovery of its Medicinal Product Candidates ("MPCs"). Mondobiotech's proprietary Search&Match bio-mathematical technology platform searches, analyzes and matches scientific journals and publications to the pathophysiological signs and symptoms of rare

diseases. This platform is derisked relative to traditional drug discovery processes by significantly reducing research time and costs.

- A continuously growing Community of doctors, scientists and patients that share with Mondobiotech their knowledge and actively collaborate and validate the results for the Search& Match discovery.
- Licensing and collaborations of such validated MPCs with strategic partners, at different stages of development. Mondobiotech signed in the past collaborations and license agreements for its MPCs with Intermune Inc., Biogen Idec Inc. and Lung Rx LLC, a subsidiary of United Therapeutics Corp., (all listed at the NASDAQ). Mondobiotech currently partners with Pharma Rare SA its Drug Resistant Tuberculosis project.

Strategic alliances and outsourcing

The company outsources through strategic alliances all non-core activities optimizing internal structural flexibility, know-how and costs. Quality of non-core activities is directly controlled by our management and through strict partner selection processes.

Validations

10 Orphan Medicinal Products Designations (Europe) and Orphan Drug Designations (USA) overall, 17 patents granted and 22 patent families under examination, at different stages. Mondobiotech was awarded Technology Pioneer 2008 by the WEF (World Economic Forum) for its vision, business model and potential impact on world health.

Management

Ruggero Gramatica - Chief Executive Officer
Dr. Dorian Bevec - Chief Scientific Officer & Founder
Paolo Barbieri - Chief Financial Officer
Maria Teresa D'Antonangelo Bühlmann- Corporate Affairs & Business Support
Dr. David Alan Cox – Head of Business Development & Licensing

Board of directors

Robert E. Patterson – Chairman - Managing Director, Peninsula Venture Silicon Valley
Prinz Michael von und zu Liechtenstein - Vice Chairman – Chairman Biopharma Invest AG
Prof. Dr. Michael A. Keller - Stanford University Librarian
Graf Francis von Seilern-Aspang - CEO Industrie u. Finanzkontor
Ruggero Gramatica - Chief Executive Officer mondoBIOTECH holding AG
Marc Häsler – Etude Hasler and H&B Law
Vincenzo Romano – MC Consulting (Suisse) Sagl

Stock information

Mondobiotech is listed as RARE
on SIX, the Swiss Stock Exchange
Swiss security number: 10191073
ISIN: CH0101910732
SIX ticker symbol: RARE

Current Pipeline ready for licensing



The company has additional 73 MPCs in various development stages.

Contact Information

mondobiotech holding AG
 Muergstrasse 18
 CH-6370 Stans
 Switzerland

T. +41 (0)840 200 010
 F. +41 (0)840 200 011
info@mondobiotech.com
www.mondobiotech.com